Naloxone Ameliorates Spatial Memory Deficits and Hyperthermia Induced by a Neurotoxic Methamphetamine Regimen in Male Rats.
Hyperthermia
Methamphetamine Hydrochloride
Naloxone Hydrochloride
Spatial Memories
Journal
Galen medical journal
ISSN: 2322-2379
Titre abrégé: Galen Med J
Pays: Iran
ID NLM: 101625418
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
04
2018
revised:
13
08
2018
accepted:
03
09
2018
entrez:
1
9
2021
pubmed:
15
4
2019
medline:
15
4
2019
Statut:
epublish
Résumé
Methamphetamine (METH) as a synthetic psychostimulant is being increasingly recognized as a worldwide problem, which may induce memory impairment. On the other hand, it is well established that naloxone, an opiate antagonist, has some beneficial effects on learning and memory. The present research aimed at evaluating naloxone effects on spatial learning and memory impairment triggered by a neurotoxic regimen of METH in male rats. The animals received the subcutaneous (sc) regimen of METH (4×6 mg/kg at 2-h intervals), intraperitoneal (ip) naloxone (4×1 mg/kg at 2-h intervals), or normal saline at four events. The Nal-METH group of rats received four naloxone injections (1 mg/ kg, ip) 30 min before each METH injection (6 mg/kg, sc) at 2-h intervals. Seven days later, they were evaluated for spatial learning and memory in the Morris Water Maze (MWM) task. METH regimen induced hyperthermia, as well as a poor performance, in the acquisition and retention phases of the task, indicating spatial learning and memory impairment compared to the controls. Naloxone administration (1 mg/kg, ip) before each METH injection led to significant attenuations of both hyperthermia and METH adverse effects on the rat performance in the MWM task. The results revealed that pretreatment with the opiate antagonist naloxone could prevent METH adverse effects on body temperature and memory performance. It seems that the opioidergic system and hyperthermia may, at least partially, be involved in METH effects on spatial memory.
Sections du résumé
BACKGROUND
BACKGROUND
Methamphetamine (METH) as a synthetic psychostimulant is being increasingly recognized as a worldwide problem, which may induce memory impairment. On the other hand, it is well established that naloxone, an opiate antagonist, has some beneficial effects on learning and memory. The present research aimed at evaluating naloxone effects on spatial learning and memory impairment triggered by a neurotoxic regimen of METH in male rats.
MATERIALS AND METHODS
METHODS
The animals received the subcutaneous (sc) regimen of METH (4×6 mg/kg at 2-h intervals), intraperitoneal (ip) naloxone (4×1 mg/kg at 2-h intervals), or normal saline at four events. The Nal-METH group of rats received four naloxone injections (1 mg/ kg, ip) 30 min before each METH injection (6 mg/kg, sc) at 2-h intervals. Seven days later, they were evaluated for spatial learning and memory in the Morris Water Maze (MWM) task.
RESULTS
RESULTS
METH regimen induced hyperthermia, as well as a poor performance, in the acquisition and retention phases of the task, indicating spatial learning and memory impairment compared to the controls. Naloxone administration (1 mg/kg, ip) before each METH injection led to significant attenuations of both hyperthermia and METH adverse effects on the rat performance in the MWM task.
CONCLUSION
CONCLUSIONS
The results revealed that pretreatment with the opiate antagonist naloxone could prevent METH adverse effects on body temperature and memory performance. It seems that the opioidergic system and hyperthermia may, at least partially, be involved in METH effects on spatial memory.
Identifiants
pubmed: 34466469
doi: 10.31661/gmj.v0i0.1182
pmc: PMC8343598
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1182Informations de copyright
Copyright© 2019, Galen Medical Journal.
Références
Pharmacol Ther. 2014 Oct;144(1):28-40
pubmed: 24836729
Psychopharmacology (Berl). 2007 Sep;194(1):21-32
pubmed: 17514479
Pharmacol Biochem Behav. 1990 Jun;36(2):345-50
pubmed: 2356207
Eur J Pharmacol. 2016 Sep 5;786:1-9
pubmed: 27235295
Brain Res. 2004 Jan 16;996(1):111-6
pubmed: 14670637
Pharmacol Biochem Behav. 1994 Feb;47(2):265-71
pubmed: 8146217
Planta Med. 2016 Nov;82(17):1482-1486
pubmed: 27433883
Psychopharmacology (Berl). 1980;69(1):111-5
pubmed: 6248917
Life Sci. 1976 May 1;18(9):971-5
pubmed: 1271966
Neurobiol Learn Mem. 2015 Sep;123:140-8
pubmed: 26079215
Biomed Pharmacother. 2017 Mar;87:489-495
pubmed: 28073098
Psychopharmacology (Berl). 1984;82(3):237-40
pubmed: 6425907
Neurosci Lett. 2016 Apr 21;619:60-7
pubmed: 26944454
Brain Res Bull. 1991 Aug;27(2):219-23
pubmed: 1660336
Psychopharmacology (Berl). 2008 Sep;199(4):637-50
pubmed: 18509623
Synapse. 2013 May;67(5):245-57
pubmed: 23280858
Neuropsychopharmacology. 2013 Jan;38(2):259-74
pubmed: 22948978
Pharmacol Biochem Behav. 1983 Sep;19(3):397-401
pubmed: 6634889
Nature. 1993 Jan 7;361(6407):31-9
pubmed: 8421494
Brain Res. 2000 Jan 31;854(1-2):224-9
pubmed: 10784126
Can J Physiol Pharmacol. 1978 Jun;56(3):483-9
pubmed: 667723
Addict Behav. 2006 Aug;31(8):1469-76
pubmed: 16309848
Nature. 1993 Jun 3;363(6428):451-4
pubmed: 8099201
J Physiol. 2008 Oct 1;586(19):4751-62
pubmed: 18703579
Neuroscience. 2007 Mar 30;145(3):824-31
pubmed: 17289274
Pharmacol Res. 2010 Nov;62(5):450-6
pubmed: 20553881
Synapse. 2003 Aug;49(2):89-96
pubmed: 12740864
Eur J Pharmacol. 1985 Jun 19;112(3):331-7
pubmed: 4040469
Pharmacol Biochem Behav. 1990 Jul;36(3):521-5
pubmed: 2377653
Addict Health. 2016 Jul;8(3):145-156
pubmed: 28496953
J Psychoactive Drugs. 2002 Jul-Sep;34(3):313-9
pubmed: 12422943
Inflammation. 2016 Feb;39(1):405-412
pubmed: 26490968
J Chem Neuroanat. 2018 Apr;89:43-50
pubmed: 29524607
Am J Addict. 2000 Summer;9(3):222-31
pubmed: 11000918
Behav Pharmacol. 2015 Jun;26(4):383-92
pubmed: 25563202
Eur J Pharmacol. 1995 Feb 24;275(1):9-16
pubmed: 7774666